HomeNewsOral insulin

Oral Insulin

Jump to

Biosimilar insulin Glargine to make $100 m from FY18: Biocon

Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.
Oral insulin to remain a pin prick for pharma cos' research

A breakthrough in oral insulin will mean doing away with insulin injections all together which explains the flurry of activity in the field. CNBC-TV18's Archana Shukla reports on just how far this research has progressed.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Oral Insulin

Biosimilar insulin Glargine to make &#36;100 m from FY18: Biocon

Oral insulin to remain a pin prick for pharma cos' research

Biosimilar insulin Glargine to make $100 m from FY18: Biocon